Abstract: System Stage, and Optical Hall Effect (OHE) system method for evaluating such as free charge carrier effective mass, concentration, mobility and free charge carrier type in a sample utilizing a permanent magnet at room temperature.

Abstract: The present invention relates to ellipsometer and polarimeter systems, and more particularly is an ellipsometer or polarimeter or the like system which operates in a frequency range between 300 GHz or lower and extending to higher than at least 1 Tera-hertz (THz), and preferably through the Infra-red (IR) range up to, and higher than 100 THz, including: a source such as a backward wave oscillator; a Smith-Purcell cell; a free electron laser, or an FTIR source and a solid state device; and a detector such as a Golay cell; a bolometer or a solid state detector; and preferably including at least one odd-bounce polarization state image rotating system, and optionally including a polarizer, at least one compensator and/or modulator, in addition to an analyzer.

Abstract: A method of applying an ellipsometer or polarimeter system which operates in a frequency range between 300 GHz or lower and extending to higher than at least 1 Tera-hertz (THz), and preferably through the Infra-red (IR) range up to, and higher than 100 THz; wherein the ellipsometer or polarimeter system includes a source such as a backward wave oscillator, a Smith-Purcell cell, a free electron laser, an FTIR source or a solid state device; and a detector such as a Golay cell a bolometer or a solid state detector; and preferably includes at least one odd-bounce polarization state image rotating system and a polarizer, and at least one compensator and/or modulator, in addition to an analyzer.

Abstract: The present invention relates to ellipsometer and polarimeter systems, and more particularly is an ellipsometer or polarimeter or the like system which operates in a frequency range between 300 GHz or lower and extending to higher than at least 1 Tera-hertz (THz), and preferably through the Infra-red (IR) range up to, and higher than 100 THz, including: a source such as a backward wave oscillator; a Smith-Purcell cell; a free electron laser, or an FTIR source and a solid state device; and a detector such as a Golay cell; a bolometer or a solid state detector; and preferably including at least one odd-bounce polarization state image rotating system, and optionally including a polarizer, at least one compensator and/or modulator, in addition to an analyzer.

Abstract: The present invention provides modified viral genomes for use as vaccines or vectors, which are improved in their ability to retain attenuating mutations. The genomes are from viruses that replicate by way of an RNA-dependent RNA or DNA polymerase. The genomes are modified in the pol gene to encode polymerases that catalyze slower replication, have increased transcriptional fidelity, or are otherwise altered such that the reversion rate of the modified virus to a non-attenuated form is decreased as compared to an equivalent, unmodified virus. In particular, modified coxsackievirus genomes are disclosed.

Abstract: A composition for facilitating delivery of biological agents, comprising a therapeutic or diagnostic agent and a supramolecular complex, the latter comprising (i) a block copolymer, having at least one nonionic, water soluble segment and at least one polyionic segment, and (ii) at least one charged surfactant having hydrophobic groups. The charge of the surfactant is opposite to the charge of the polyionic segment of the block copolymer. The constituents of the supramolecular complex are bound by interaction between the opposite charges thereof and between surfactant hydrophobic groups. The therapeutic or diagnostic agent may be an ionic substance, in which case the ionic substance has a net charge opposite to that of the block copolymer, the net charge being no more than 10.

Abstract: Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens assocated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.

Abstract: The present invention provides polymer micelles with cross-linked ionic cores as delivery vehicles for therapeutics, diagnostics, nucleic acids, proteins, small molecules and the like. The present invention provides additionally methods of synthesis and uses for such micelles.

Abstract: The present invention discloses novel monomeric compositions which are substituted quinoline- or quinazoline-based structures capable of hydrogen bonding specifically with interstrand purine-pyrimidine base pairs in a double-stranded Watson-Crick DNA molecule. Furthermore, the novel monomeric compounds of the present invention are capable of being assembled in specific sequences into oligomers capable of binding with sequence specificity to duplex DNA via a triple helix motif.

Abstract: Antisense oligonucleotides and composition of oligonucleotides are taught which inhibit the proliferation of cells without affecting cell viability. p53 antisense oligonucleotides are shown to inhibit the proliferation of tissue culture cells expressing this gene. Methods of treating a patient with such antisense oligonucleotides is described.

Abstract: Polypeptides derived from human interleukin-8 (IL-8) which act as therapeutic agents for the therapy of neoplastic (both solid and leukemic) and infectious diseases such as bacterial, fungal, viral and parasitic.

Abstract: The present invention relates to new bisquinolines useful in the treatment of malaria and to processes for the production thereof. The invention also relates to methods for the treatment of malaria and, in particular, to the treatment of chloroquine-resistant strains of malaria. The compounds of the invention have the following formula: ##STR1## wherein R is a bivalent radical derived from an acyclic or cyclic hydrocarbon by removal of one hydrogen atom from each of two different carbon atoms. R' is hydrogen or lower alkyl (generally containing between about 1 and about 4 carbon atoms). X is hydrogen (--H), fluoro (--F), chloro (--Cl), bromo (--Br), trifluoromethyl (--CF.sub.3), cyano (--CN), or methylsulfoxide (--SOCH.sub.3). In its acyclic form, R generally contains at least two, and no more than about 12, carbon atoms and, preferably, is an unsubstituted straight or branched alkane.